Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment

Stock Information for Mesa Air Group Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Mesa Air Group Inc.

Mesoblast to Host R&D Day on April 8, 2026
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
Ryoncil® Profits Underpinning Substantial Growth Pipeline
Mesoblast Financial Results and Corporate Update Webcast
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
Ryoncil® Net Revenues Increase for the Quarter to US$30M
FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
Mesabi Trust Press Release

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.